首页> Journal of translational medicine> CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma.

CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma.

导出 OA

翻译打印收藏纠错

第一作者： Tingdang,Liu

第一单位： Stem Cell Research Center, Shantou University Medical College, Shantou, 515041, Guangdong Province, China.

作者： Tingdang,Liu ^[1] ; Ximing,Dai ^[1] ; Yien,Xu ^[2] ; Tian,Guan ^[3] ; Liangli,Hong ^[4] ; Tahir,Zaib ^[1] ; Qi,Zhou ^[1] ; Ke,Cheng ^[1] ; Xiaoling,Zhou ^[1] ; Changchun,Ma ^[5] ; Pingnan,Sun ^[6]

作者单位： Stem Cell Research Center, Shantou University Medical College, Shantou, 515041, Guangdong Province, China. ^[1] Stem Cell Research Center, Shantou University Medical College, Shantou, 515041, Guangdong Province, China.;Cancer Hospital, Shantou University Medical College, Shantou, 515041, Guangdong Province, China. ^[2] Guangdong Procapzoom Biosciences, Inc., Shantou, 515041, Guangdong Province, China. ^[3] Department of Pathology, The First Affiliated Hospital of Shantou University Medical College, Shantou, 515041, Guangdong Province, China. ^[4] Stem Cell Research Center, Shantou University Medical College, Shantou, 515041, Guangdong Province, China. 994370958@qq.com.;Cancer Hospital, Shantou University Medical College, Shantou, 515041, Guangdong Province, China. 994370958@qq.com. ^[5] Stem Cell Research Center, Shantou University Medical College, Shantou, 515041, Guangdong Province, China. pnsun@stu.edu.cn. ^[6]

关键词 CAR-NK cell therapy CD22 Esophageal squamous cell carcinomas Immunotherapy Solid tumor